Endocrine Abstracts

For patients taking thyroxine replacement guidelines generally recommend aiming for a target TSH within the laboratory reference range. The evidence for this guidance is generally based on an extrapolation of data from patients with endogenous subclinical thyroid disease. We aimed to examine the safety of having a TSH which was either suppressed (≤0.03 mU/l), low (0.04–0.4 mU/l), ‘normal’ (0.4–4.0 mU/l) or raised (>4.0 mU/l) in a population-based ...

The TEARS database links six datasets for patients with treated and stabilised thyroid conditions. It has been validated previously and represents a population-based patient sample, as patient identification includes using regional-wide biochemical records and prescription data. For patients on long-term thyroxine we examined the outcome of ‘serious vascular events’ defined as vascular death, non-fatal myocardial infarction and non-fatal stroke as used in the Anti -t...

Objectives: (1) to establish the relative level of osteoporotic fracture in the thyroid population compared to the general population, and (2) to establish whether osteoporotic fracture in patients receiving thyroxine was associated with plasma thyroid stimulating hormone (TSH) level or thyroxine dose.Method: A database of clinical information from subjects with treated thyroid disease was linked to morbidity records describing all in-patient episodes of...